utreloxastat   Click here for help

GtoPdb Ligand ID: 13260

Synonyms: compound C9 [WO2020081879A2] | PTC-857 | PTC857
Compound class: Synthetic organic
Comment: Utreloxastat (PTC-857) is described as a 15-lipoxygenase inhibitor in its INN record. It was developed for potential to treat α-synucleinopathies, tauopathies, ALS and other brain injuries/insults [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 34.14
Molecular weight 276.41
XLogP 4.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCCCCCCC1=C(C)C(=O)C(=C(C)C1=O)C
Isomeric SMILES CCCCCCCCCC1=C(C(=O)C(=C(C1=O)C)C)C
InChI InChI=1S/C18H28O2/c1-5-6-7-8-9-10-11-12-16-15(4)17(19)13(2)14(3)18(16)20/h5-12H2,1-4H3
InChI Key IJWAQTHZBDBIID-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
PTC Therapeutics are investigating the efficacy of utreloxastat (PTC-857) as a treatment for amyotrophic lateral sclerosis (ALS). The compound was designated as an orphan drug for ALS by the FDA in April 2022.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05349721 Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS Phase 2 Interventional PTC Therapeutics